Patient input into the assessment of new medicines by Pharmac is an important topic in New Zealand, and BCAC’s Libby Burgess was pleased to hear from others with similar concerns in other Asia Pacific countries at the European Society for Medical Oncology (ESMO) Congress in Singapore.
Ann Single from Patient Voice Initiative Australia spoke of the value of genuine patient input into health technology assessment (HTA), the appraisal of the value and impacts of medicines, devices, tests and other medical interventions. This is an important topic that the Consumer and Patient Working Group in New Zealand is addressing as part of Pharmac’s Reset and Reform initiatives. Ann noted that the questions asked in the HTA process shape the knowledge or evidence sought and the outcome reached. Patients have unique and critical knowledge that illuminates, enhances and humanises the HTA processes, allowing decisions to promote an efficient, equitable and high-quality health system. Ann asked two key questions of advocates: do our HTA processes consider evidence of patient’s’ needs, preferences and experiences or are they built on assumptions that create barriers; when patients participate can HTA people and patients recognise each other’s knowledge and change perspectives or course of action as a result. The answers to these show we have a long way to go to establish meaningful patient evidence within our New Zealand HTA. However, it is heartening that Pharmac is seeking input through the newly established patient-nominated Consumer and Patient Working Group on how this can change.
